Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.

@article{Kiri2005InhaledCI,
  title={Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.},
  author={Victor Alangibi Kiri and Neil B. Pride and Joan B. Soriano and J{\o}rgen Vestbo},
  journal={American journal of respiratory and critical care medicine},
  year={2005},
  volume={172 4},
  pages={
          460-4
        }
}
  • V. Kiri, N. Pride, +1 author J. Vestbo
  • Published 15 August 2005
  • Medicine
  • American journal of respiratory and critical care medicine
RATIONALE Recent cohort studies in chronic obstructive pulmonary disease (COPD) have questioned the validity of previously reported associations between inhaled corticosteroids (ICS) and reductions in mortality and rehospitalization in observational studies. Using time-dependent versions of statistical survival models, these studies have suggested immortal time bias as responsible for the proposed beneficial association. OBJECTIVES We explored the extent of this bias in a study of patients… 
Inhaled corticosteroids in chronic obstructive pulmonary disease.
TLDR
Although future randomized trials will need to be conducted with the most rigorous methodology for all outcomes, much uncertainty remains regarding the potential benefits of ICS in COPD.
Inhaled corticosteroids and mortality in COPD.
TLDR
Therapy with ICSs reduced mortality in COPD patients; the effect was particularly notable for cardiovascular death and was short term in that it was dependent on recent exposure.
Impact of Regular Inhaled Corticosteroid Use on Chronic Obstructive Pulmonary Disease Outcomes
TLDR
Use of inhaled corticosteroids was associated with reduced risk of chronic obstructive pulmonary disease exacerbations and all-cause mortality, and this benefit was most pronounced among never-smokers and in those with evidence of co-morbid asthma.
Inhaled corticosteroids in COPD: the clinical evidence
TLDR
It is concluded that there is no survival benefit independent of the effect of long-acting bronchodilation and no effect on FEV1 decline, and that the possible benefit on reducing severe exacerbations is unclear.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.
  • S. Suissa
  • Medicine
    American journal of respiratory and critical care medicine
  • 2003
TLDR
Inhaled corticosteroid use after hospitalization for COPD was not found to reduce mortality and morbidity, and Cox's proportional hazards model was used to compare the time-fixed analysis employed in the recent studies with the alternative time-dependent analysis.
Inhaled steroids and mortality in COPD: bias from unaccounted immortal time
  • S. Suissa
  • Medicine
    European Respiratory Journal
  • 2004
TLDR
Regular inhaled corticosteroid use in chronic obstructive pulmonary disease was not found to reduce all-cause mortality, and suggestion of this benefit from a previous observational study is the result of bias from unaccounted immortal time in its cohort design and analysis.
Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.
  • V. Fan, C. Bryson, +4 authors D. Au
  • Medicine
    American journal of respiratory and critical care medicine
  • 2003
TLDR
A prospective cohort study of patients with COPD, using time-dependent methods to determine whether use of inhaled corticosteroids more than 80% of the time reduced the risk of all-cause mortality and COPD exacerbations, found no association between inhaled Corticosteroid use and hospitalizations or exacerbations due to COPD.
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
TLDR
Use of inhaled corticosteroids following hospital discharge for chronic obstructive pulmonary disease was associated with a significant reduction in the overall mortality rate, and low- was inferior to medium- or high-dose therapy in protecting against mortality in chronic obstructives pulmonary disease.
Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD
TLDR
Very low doses of inhaled corticosteroids may be associated with a reduction in the risk of acute myocardial infarction, as observed for doses ranging 50–200 µg·day−1.
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice
TLDR
Regular use of fluticasone propionate alone or in combination with salmeterol is associated with increased survival of chronic obstructive pulmonary disease patients managed in primary care.
Inhaled corticosteroid use in asthma and the prevention of myocardial infarction.
Inhaled Corticosteroids With/Without Long-Acting β-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients
TLDR
Use of inhaled corticosteroids with/without long-acting β-agonists was associated with a reduction of rehospitalization or death in COPD patients.
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.
TLDR
Inhaled triamcinolone does not slow the rate of decline in lung function in people with COPD, but it improves airway reactivity and respiratory symptoms and decreases the use of health care services for respiratory problems.
The TORCH (TOwards a Revolution in COPD Health) survival study protocol
  • J. Vestbo
  • Medicine
    European Respiratory Journal
  • 2004
TLDR
The “TOwards a Revolution in COPD Health” study is aiming to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients and explains the rationale behind it.
...
1
2
3
4
5
...